强化包膜在MRI诊断肝细胞癌中的价值:对简化LI-RADS的意义
该回顾性研究纳入735例患者986个观察灶,评估强化包膜作为肝细胞癌主要特征的价值及简化LI-RADS v2018的两种策略。强化包膜与肝细胞癌显著相关(细胞外对比剂MRI DOR=16.6,肝胆对比剂MRI DOR=9.3)。将强化包膜等同于其他主要特征可提高敏感度而不显著降低特异度,尤其在细胞外对比剂MRI上。
要点
- 强化包膜与肝细胞癌显著相关,是维持LI-RADS v2018敏感度的关键特征。
- 将强化包膜等同于其他主要特征可提高敏感度且不显著降低特异度。
- 细胞外对比剂MRI上敏感度提升比肝胆对比剂MRI更明显。
核心结论
- 强化包膜与肝细胞癌强相关,对维持LI-RADS v2018敏感度至关重要;将其等同于其他主要特征可简化LI-RADS并提高敏感度,尤其在细胞外对比剂MRI上。
研究设计与样本
- 回顾性研究,纳入735例患者(中位年龄60岁,四分位距54-66岁,562名男性)共986个观察灶,均于术前1个月内接受MRI。150例(20.4%)接受细胞外对比剂MRI,585例(79.6%)接受肝胆对比剂MRI。两名放射科医师独立分配LI-RADS类别,以共识解决分歧。
诊断标准与关键数值
- 强化包膜与肝细胞癌的关联:细胞外对比剂MRI诊断比值比DOR=16.6(p<0.001),肝胆对比剂MRI DOR=9.3(p<0.001)。
- LI-RADS[EC(+)]策略敏感度:细胞外对比剂MRI 81.3% vs LI-RADS v2018 78.4%(p=0.047);肝胆对比剂MRI 74.2% vs 72.7%(p=0.005)。
- LI-RADS[EC(+)]策略特异度:细胞外对比剂MRI 96.7% vs 96.7%(p>0.99);肝胆对比剂MRI 91.7% vs 92.1%(p=0.26),均无显著差异。
- LI-RADS[EC(-)]策略敏感度:细胞外对比剂MRI 74.8% vs 78.4%(p=0.03);肝胆对比剂MRI 72.3% vs 72.7%(p=0.17),特异度无增益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: We evaluated the value of EC as a major feature for hepatocellular carcinoma (HCC) and its implications on simplifying LI-RADS v2018: by either excluding EC (LI-RADS[EC(-)]), or treating EC as equivalent to other major features (LI-RADS[EC(+)]).
MATERIALS AND METHODS: This retrospective study included patients who underwent preoperative MRI within 1 month of surgery. Two radiologists independently assigned LI-RADS categories, with consensus resolution. The association between EC and HCC was evaluated by diagnostic odds ratio (DOR). Sensitivity and specificity of LI-RADS[EC(-)] and LI-RADS[EC(+)] were compared to LI-RADS v2018 using generalized estimating equations.
RESULTS: Among 735 patients (median [interquartile range] age, 60 [54-66] years, 562 men) with 986 observations, 150 (20.4%) underwent extracellular contrast (ECA)-MRI and 585 (79.6%) underwent hepatobiliary contrast (HBA)-MRI. EC was significantly associated with HCC on both ECA-MRI (DOR = 16.6, p < 0.001) and HBA-MRI (DOR = 9.3, p < 0.001). LI-RADS[EC(+)] strategy demonstrated significantly higher sensitivity than LI-RADS v2018 on both ECA-MRI (81.3% vs. 78.4%, p = 0.047) and HBA-MRI (74.2% vs. 72.7%; p = 0.005), without significant differences in specificity (96.7% vs. 96.7%; p > 0.99 for ECA-MRI and 91.7% vs. 92.1%; p = 0.26 for HBA-MRI). However, LI-RADS[EC(-)] yielded a lower sensitivity (74.8% vs. 78.4%; p = 0.03 for ECA-MRI and 72.3% vs. 72.7%; p = 0.17 for HBA-MRI) without a gain in specificity.
CONCLUSION: EC is strongly associated with HCC and critical for maintaining the sensitivity of the LI-RADS v2018. Treating EC as equivalent to other major features may simplify LI-RADS and improve sensitivity, particularly on ECA-MRI, where the increase in sensitivity was more pronounced than on HBA-MRI.
KEY POINTS: Question Can LIRADS v2018 be simplified by considering enhancing capsule (EC) as equivalent to other major features (i.e., non-peripheral washout), regardless of observation size? Findings Treating EC as equivalent to other major features yielded higher sensitivity than LIRADS v2018 on both extracellular- and hepatobiliary contrast-enhanced MRI, without significantly compromising specificity. Clinical relevance EC is a key feature for hepatocellular carcinoma diagnosis. The strategy of treating EC as equivalent to other major features can be used to increase diagnostic sensitivity as well as simplify LI-RADS v2018, particularly on extracellular contrast-enhanced MRI.
引用
- Choi SJ, Kim HY, Lee SJ, et al. Value of enhancing capsule for diagnosing hepatocellular carcinoma on MRI: implications for simplifying LI-RADS. Eur Radiol. 2025. PMID: 40847079. doi:10.1007/s00330-025-11938-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。